Fostamatinib (TAK-632/R788)

About Nippon Shinyaku

Nippon Shinyaku is a well-established, revenue-generating Japanese pharmaceutical company with a strategic focus on creating novel treatments for unmet medical needs. Its commercial success is anchored by Viltepso, an exon-skipping therapy for Duchenne muscular dystrophy, alongside other marketed products. The company leverages its research expertise to advance a pipeline spanning rare genetic diseases, oncology, and metabolic conditions, aiming for sustainable growth through both internal R&D and strategic partnerships.

Therapeutic Areas

Other Immune Thrombocytopenia (ITP) Drugs